Press Release Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers 8 hours ago
Press Release Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models Aug 6
Press Release Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program Aug 5